CLS Q3 (Review): Soft sales, but better quarters ahead - Redeye
Börskollen - Aktier, fonder och ekonominyheter
BörskollenFör dig med koll på börsen

Analys

CLS Q3 (Review): Soft sales, but better quarters ahead - Redeye

{newsItem.title}

Redeye provides an update following CLS’s Q3 2025 report. Sales came in well below our expectations; however, we believe this is only a temporary setback, with stronger quarters ahead. Following the report, we have made some estimate adjustments, resulting in a slightly revised fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1139225/cls-q3-review-soft-sales-but-better-quarters-ahead?utm_source=finwire&utm_medium=RSS

Nyheter om Clinical Laserthermia

Läses av andra just nu

Om aktien Clinical Laserthermia

Senaste nytt